Please login to the form below

Not currently logged in
Email:
Password:

veliparib

This page shows the latest veliparib news and features for those working in and with pharma, biotech and healthcare.

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

Also looking to carve a piece of the PARP inhibitor market in ovarian cancer is AbbVie, who also revealed positive data in this therapy area with its candidate veliparib.

Latest news

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics